In a previous proof of concept report, we proposed a novel immunomodulatory strategy consisting in the local low-dose delivery of an IL-10-inducing formulation (containing VitD/Dexa) as a form of immune intervention for atherosclerosis (30). Here, IL10 is linked to atherosclerosis.